NCT00632086

Brief Summary

Study to determine a single dose bioavailablity of PA32540 is similar to EC aspirin 325 mg with respect to salicylic acid.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P50-P75 for phase_1 healthy

Timeline
Completed

Started Feb 2008

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

February 29, 2008

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 10, 2008

Completed
Last Updated

March 10, 2008

Status Verified

February 1, 2008

Enrollment Period

Same day

First QC Date

February 29, 2008

Last Update Submit

March 7, 2008

Conditions

Keywords

PK

Study Arms (3)

1

EXPERIMENTAL

Single oral dose of 325 mg aspirin administered as PA32540

Drug: PA32540

2

EXPERIMENTAL

aspirin core

Drug: aspirin component of PA32540

3

ACTIVE COMPARATOR

active

Drug: Ecotrin

Interventions

1

The 325 mg aspirin component of PA32540

2

325 mg Ecotrin

3

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Standard for PK
  • Ages 18-55 years old
  • Males and females

You may not qualify if:

  • Standard for PK

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Aspirin

Intervention Hierarchy (Ancestors)

SalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 29, 2008

First Posted

March 10, 2008

Study Start

February 1, 2008

Primary Completion

February 1, 2008

Study Completion

February 1, 2008

Last Updated

March 10, 2008

Record last verified: 2008-02